Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,904 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: AstraZeneca Clear all
Recruiting Phase 2 Interventional

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan, Nanoliposomal Irinotecan, Gemcitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Orange, California • Palo Alto, California • Santa Rosa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01323790
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
68
States / cities
Mobile, Alabama • Pell City, Alabama • Mesa, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 1 Interventional

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

NCT03333824
View directory record Official record
Conditions
Solid Tumours
Interventions
CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Results available

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

NCT01597388
View directory record Official record
Conditions
Advanced Metastatic Breast Cancer
Interventions
AZD2014, Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
5
States / cities
Sarasota, Florida • Detroit, Michigan • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

NCT00891462
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
104
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 1 Interventional

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

NCT03122496
View directory record Official record
Conditions
Metastatic Anaplastic Thyroid Cancer
Interventions
durvalumab, tremelimumab, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

NCT04630756
View directory record Official record
Conditions
Advanced Haematological Malignancies
Interventions
AZD4573, Acalabrutinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Duarte, California • La Jolla, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 4 Interventional Results available

Adherence Study in COPD Patients

NCT02864342
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD
Interventions
Arm 1: BreatheMate device with application, Arm 2: BreatheMate device without application
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Clearwater, Florida • Tampa, Florida • Marlton, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

NCT00894322
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

NCT05459688
View directory record Official record
Conditions
Hypertension
Interventions
CIN-107
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
36
States / cities
Saraland, Alabama • Huntington Park, California • Lincoln, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

NCT02406261
View directory record Official record
Conditions
Healthy
Interventions
Lanabecestat, Simvastatin, Midazolam, Donepezil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 30, 2026, 2:51 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

NCT05138133
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
16
States / cities
Glendale, Arizona • La Palma, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas

NCT00822887
View directory record Official record
Conditions
Malignant Gliomas
Interventions
Vandetanib, Fractionated Stereotactic Radiotherapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 30, 2026, 2:51 AM EDT
Terminated Phase 1 Interventional

Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

NCT00473616
View directory record Official record
Conditions
Advanced Solid Tumors, Cancer, Advanced Solid Malignancies
Interventions
AZD7762, Irinotecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 11, 2011 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

NCT03557307
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
23
States / cities
Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 1 Interventional

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

NCT04155645
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD8233 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chula Vista, California • Glendale, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 30, 2026, 2:51 AM EDT
Recruiting Phase 2 Interventional

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

NCT04499053
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 30, 2026, 2:51 AM EDT
Recruiting Phase 3 Interventional

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

NCT07711002
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
42
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 2:51 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

NCT05056727
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
42
States / cities
Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

NCT01225562
View directory record Official record
Conditions
Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
Interventions
Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
21,379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
250
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 30, 2026, 2:51 AM EDT
Completed No phase listed Observational

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

NCT02239666
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
NIS
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

NCT01147666
View directory record Official record
Conditions
End Stage Renal Disease, Anemia
Interventions
Roxadustat, Epoetin Alfa, Placebo
Drug · Other
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

NCT01258205
View directory record Official record
Conditions
Crohn's Disease
Interventions
AMG 139
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
4
States / cities
Berlin, New Jersey • Stony Brook, New York • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 30, 2026, 2:51 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

NCT03490669
View directory record Official record
Conditions
Advanced Solid Tumors, Pancreatic Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
Interventions
MSC-1
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Scottsdale, Arizona • Grand Rapids, Michigan • Middletown, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 30, 2026, 2:51 AM EDT